Factors associated with the progression of fibrosis on liver biopsy in Alaska Native and American Indian persons with chronic hepatitis C

Canadian Journal of Gastroenterology

Volumn 24, Issue 7, 2010, Pages 445-451

  Livingston, Stephen E ^a   Deubner, Heike ^b   Bruden, Dana L ^c   McMahon, Brian J ^a,c   Homan, Chriss E ^a   Townshend Bulson, Lisa J ^a   Bruce, Michael G ^c   Hennessy, Thomas W ^c   Williams, James L ^a   Gretch, David R ^b  

^a ALASKA NATIVE TRIBAL HEALTH CONSORTIUM   (United States)

^b UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^c CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

Author keywords

Hepatitis C; Liver fibrosis; Liver steatosis

Indexed keywords

ALANINE AMINOTRANSFERASE; ALPHA FETOPROTEIN; ASPARTATE AMINOTRANSFERASE; VIRUS RNA;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; AMERICAN INDIAN; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DISEASE COURSE; DISEASE DURATION; DISEASE SEVERITY; FATTY LIVER; FEMALE; GROUPS BY AGE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; LIVER BIOPSY; LIVER FIBROSIS; LIVER HISTOLOGY; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PREDICTOR VARIABLE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RISK FACTOR; SCORING SYSTEM; UNITED STATES;

EID: 77955005135     PISSN: 08357900     EISSN: None     Source Type: Journal    
DOI: 10.1155/2010/692036     Document Type: Article

References (23)

1. Wright M, Goldin R, Fabre A, et al. Measurement and determinants of the natural history of liver fibrosis in hepatitis C virus infection: A cross-sectional and longitudinal study. Gut 2003;52:574-9.
2. Poynard T, Ratziu V, Charlotte F, Goodman Z, McHutchison J, Albrecht J. Rates and risk factors of liver fibrosis progression in patients with chronic hepatitis C. J Hepatol 2001;34:730-9.
3. Danta M, Dore GJ, Hennessy L, et al. Factors associated with severity of hepatic fibrosis in people with chronic hepatitis C infection. Med J Aust 2002;177:240-5.
4. Bruce MG, Bruden D, McMahon BJ, et al. Clinical significance of elevated alpha-fetoprotein in Alaska Native patients with chronic hepatitis C. J Viral Hepatol 2008;15:179-87.
5. Minola E, Prati D, Suter F, et al. Age at infection affects the long-term outcome of transfusion-associated chronic hepatitis C. Blood 2002:99:4588-91.
6. Monto A, Patel K, Bostrom A, et al. Risks of a range of alcohol intake on hepatitis C-related fibrosis. Hepatology 2004;39:826-34.
7. McCormick SE, Goodman ZD, Maydonovitch CL, Sjogren MH. Evaluation of liver histology, ALT elevation, and HCV RNA titer in patients with chronic hepatitis C. Am J Gastroenterol 1996;91:1516-22.
8. Poynard T, Bedossa P, Opolon P. Natural history of liver fibrosis progression in patients with chronic hepatitis C. Lancet 1997;349:825-30.
9. McMahon BJ, Hennessy T, Christensen C, et al. Epidemiology and risk factors for hepatitis C in Alaska Natives. Hepatology 2004;39:324-32.
10. Strader DB, Wright T, Thomas DL, Seeff L. Diagnosis, management and treatment of hepatitis C. Hepatology 2004;39:1147-71.
11. Davidson F, Simmonds P, Ferguson JC, et al. Survey of major genotypes and subtypes of hepatitis C virus using RFLP of sequences amplified from the 5′ non-coding region. J Gen Virol 1995;76:1197-204.
12. Knodell RG, Ishak KG, Black WC, et al. Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis. Hepatology 1981;1:431-5.
13. Ishak K, Baptista A, Bianchi L, et al. Histological grading and staging of chronic hepatitis. J Hepatol 1995;22:696-9.
14. Bruden D, McMahon BJ, Hennessy TW, et al. Estimating the date of hepatitis C virus infection from patient interviews and antibody tests on stored sera. Am J Gastroenterol 2004;99:1518-22.
15. Livingston SE, Deubner H, McMahon BJ, et al. Steatosis and hepatitis C in an Alaska Native/American Indian population. Int J Circumpolar Health 2006;6:253-60.
16. Cholet F, Nousbaum JB, Richecoeur M, et al. Factors associated with liver steatosis and fibrosis in chronic hepatitis C patients. Gastroenterol Clin Biol 2004;28:272-8.
17. Westin J, Nordlinder H, Lagging M, Norkrans G, Wejstal R. Steatosis accelerates fibrosis development over time in hepatitis C virus genotype 3 infected patients. J Hepatol 2002;37:837-42.
18. Adinolfi L, Gambardella M, Andreana A, Tripodi MF, Utili R, Ruggiero G. Steatosis accelerates the progression of liver damage of chronic hepatitis C patients and correlates with specific HCV genotype and visceral obesity. Hepatology 2001;33:1358-63.
19. Hu K-Q, Hyulo N, Esrailian E, et al. Overweight and obesity, hepatic steatosis, and progression of chronic hepatitis C: A retrospective study on a large cohort of patients in the United States. J Hepatol 2004;40:147-54.
20. Kita Y, Mizukoshi E, Takamura T, et al. Impact of diabetes mellitus on prognosis of patients infected with hepatitis C virus. Metabolism 2007;56:1682-8.
21. Papatheodoridis GV, Chrysanthos N, Savvas S, et al. Diabetes mellitus in chronic hepatitis B and C: Prevalence and potential association with the extent of liver fibrosis. J Viral Hepatol 2006;13:303-10.
22. Gordon SC, Elloway RS, Long JC, Dmuchowski CF. The pathology of hepatitis C as a function of mode of transmission: Blood transfusion vs. intravenous drug use. Hepatology 1993;18:1338-43.
23. Wong JB, Koff RS. Watchful waiting with periodic liver biopsy versus immediate empirical therapy for histologically mild chronic hepatitis C. A cost-effectiveness analysis. Ann Intern Med 2000;133:665-75.